Alopecia Areata Market Forecast Signals Robust Industry Growth Through 2036 - DelveInsight

The Alopecia Areata market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alopecia Areata pipeline products will significantly revolutionize the Alopecia Areata market dynamics.

DelveInsight's "Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Alopecia Areata market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2022 to 2036. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Alopecia Areata market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alopecia Areata Market Forecast
https://www.delveinsight.com/sample-request/alopecia-areata-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Alopecia Areata Market Report:
• The Alopecia Areata market size across the 7MM was valued at approximately USD 850 million in 2025 and is projected to expand at a robust CAGR of 24.4% during 2022-2036.
• In January 2026, Legacy Healthcare reported plans to advance its topical solution Coacillium (LH-8) into an international Phase III clinical trial for Alopecia Areata, following clearance from the US FDA.
• In August 2025, AbbVie's leading Janus kinase (JAK) inhibitor, Rinvoq (upadacitinib), achieved its primary endpoints in a second Phase III trial for alopecia areata. In Study 1 of the UP-AA program (NCT06012240), the therapy showed a significant improvement in scalp hair regrowth, with 45.2% of patients on the 15mg dose and 55% on the 30mg dose reaching 80% scalp hair coverage after 24 weeks of treatment, as assessed using the Severity of Alopecia Tool (SALT) scores.
• In July 2025, AbbVie (NYSE: ABBV) has announced positive topline results from the first of two pivotal Phase 3 UP-AA clinical trials, which are assessing the safety and effectiveness of upadacitinib (RINVOQ®; 15 mg and 30 mg once daily) in adults and adolescents with severe alopecia areata (AA). Participants in the study had a mean baseline SALT score of 83.8, indicating roughly 16% scalp hair coverage.
• In May 2025, A siRNA-based treatment for alopecia areata, developed by researchers Anastasia Khvorova, PhD; John Harris, MD, PhD'05; Julia Alterman, PhD; and Qi Tang, PhD, at UMass Chan Medical School and licensed to Alys Pharmaceuticals Inc., has now been administered to the first participant in a Phase IIa clinical trial. Alys Pharmaceuticals-a Boston-based biotech company formed through the merger of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, NIRA Biosciences, and Vimela Therapeutics-is advancing ALY-101, its first clinical candidate from a pipeline of siRNA therapies focused on dermatology.
• In March 2025, Findings from the Phase III BRAVE-AA-PEDS trial (NCT05723198) reveal that adolescents with severe alopecia areata (AA) treated with once-daily baricitinib (Olumiant) saw substantial hair regrowth on the scalp, eyebrows, and eyelashes after 36 weeks. Remarkably, the data suggest that this younger group responded more quickly to baricitinib than adult patients with severe AA.
• In March 2025, Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) have announced late-breaking results from the Phase 3 BRAVE-AA-PEDS study, showing that adolescents (ages 12 to under 18) with severe alopecia areata (AA) experienced significant hair regrowth on the scalp, eyebrows, and eyelashes after 36 weeks of once-daily oral treatment with baricitinib at 4 mg and 2 mg doses. These findings were presented during a late-breaker session at the American Academy of Dermatology (AAD) Annual Meeting.
• In 2025, the alopecia areata market size in the US was around USD 500 million, accounting for 53% of the total market. This figure is expected to grow significantly with the introduction of emerging therapies.
• The total market size of EU4 and the UK was estimated to be approximately USD 300 million in 2025, which was nearly 39% of the total market revenue for the 7MM.
• Among EU4 and the UK, the UK accounted for the highest market share with approximately USD 90 million in 2025, followed by Germany with approximately USD 55 million in the respective year, and France, capturing the least market with nearly USD 40 million in 2025.
• In 2025, the total market size of alopecia areata was approximately USD 60 million in Japan which is anticipated to increase during the forecast period (2026-2036).
• In 2025, the US accounted for the highest prevalent cases of alopecia areata with approximately 800,000 cases, which are expected to increase by 2036.
• In 2025, the UK reported the highest number of diagnosed prevalent cases of alopecia areata among EU4 and the UK, with approximately 330,000 cases. Spain followed with around 180,000 cases, while Italy recorded the lowest diagnosed prevalence, with nearly 100,000 cases.
• In 2025, Japan reported approximately 170,000 thousand diagnosed prevalent cases of alopecia areata in females and nearly 110,000 cases in males, with numbers projected to rise by 2036.
• In 2025, females accounted for 63% of alopecia areata cases in EU4 and the UK, while males represented 37%. These gender-specific patterns are expected to grow, with overall prevalence projected to increase by 2036.
• In 2025, around 14% of alopecia areata cases in EU4 and the UK were mild, 45% moderate, and 41% severe. These severity patterns are expected to continue, with overall prevalence anticipated to increase by 2036.
• Key Alopecia Areata Companies: Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others
• Key Alopecia Areata Therapies: OLUMIANT (baricitinib), LITFULO (ritlecitinib), Etrasimod, Coacillium (LH-8), PF-06651600, ADX-914, Upadacitinib, Daxdilimab, CTP-543, Deucravacitinib, SHR0302, IMG-007, Jaktinib, Rezpegaldesleukin, Rosnilimab, LEO 124249, Baricitinib, and others
• The Alopecia Areata epidemiology based on gender analyzed that females and males are equally affected by Alopecia Areata
• The Alopecia Areata epidemiology based on gender analyzed that Alopecia Areata affects both males and females equally

Alopecia Areata Overview
Alopecia Areata is an autoimmune disorder that causes sudden hair loss, typically in small, round patches on the scalp or other areas of the body. The condition occurs when the immune system mistakenly attacks hair follicles, disrupting hair growth. The exact cause is unknown, but genetics and environmental factors may play a role. While the condition can be unpredictable, hair often regrows over time, although in some cases, it can lead to permanent hair loss. Treatments focus on managing symptoms and stimulating hair regrowth, but there is no cure.

Get a Free sample for the Alopecia Areata Market Report:
https://www.delveinsight.com/report-store/alopecia-areata-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Alopecia Areata Market
The dynamics of the Alopecia Areata market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2022-2036.

Alopecia Areata Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alopecia Areata Epidemiology Segmentation:
The Alopecia Areata market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Prevalent Cases of Alopecia Areata
• Diagnosed Prevalent Cases of Alopecia Areata
• Gender-specific Diagnosed Prevalent cases of Alopecia Areata
• Age Onset-based Diagnosed Prevalent cases of Alopecia Areata
• Severity-specific Diagnosed Prevalent cases of Alopecia Areata

Download the report to understand which factors are driving Alopecia Areata epidemiology trends @ Alopecia Areata Epidemiological Insights
https://www.delveinsight.com/sample-request/alopecia-areata-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Alopecia Areata Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alopecia Areata market or expected to get launched during the study period. The analysis covers Alopecia Areata market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Alopecia Areata Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alopecia Areata Therapies and Key Companies
• Deuruxolitinib (LEQSELVI): Sun Pharmaceuticals
• Ritlecitinib (LITFULO): Pfizer
• STS-01: Soterios
• Rezpegaldesleukin (NKTR-358): Nektar Therapeutics
• Coacillium (LH-8): Legacy Healthcare
• OLUMIANT (baricitinib): Eli Lilly and Company/Incyte Corporation
• LITFULO (ritlecitinib): Pfizer
• Etrasimod: Pfizer
• Coacillium (LH-8): Legacy Healthcare
• PF-06651600: Pfizer
• ADX-914: Q32 Bio Inc.
• Upadacitinib: AbbVie
• Daxdilimab: Amgen
• CTP-543: Concert Pharmaceuticals
• Deucravacitinib: Bristol-Myers Squibb
• SHR0302: Reistone Biopharma
• IMG-007: Inmagene LLC
• Jaktinib: Suzhou Zelgen Biopharma
• Rezpegaldesleukin: Nektar Therapeutics
• Rosnilimab: AnaptysBio, Inc.
• LEO 124249: LEO Pharma
• Baricitinib: Eli Lilly and Company

To know more about Alopecia Areata treatment, visit @ Alopecia Areata Medications
https://www.delveinsight.com/sample-request/alopecia-areata-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Alopecia Areata Market Strengths
• The major strength of the Alopecia areata market is its robust pipeline with the emergence of several therapies
• Increasing awareness and development to understand the diversity of the disease might improve the diagnosis of Alopecia areata, thereby resulting in a lucrative market opportunity

Alopecia Areata Market Opportunities
• Several organizations are actively working to provide information and awareness of such rare and devastating disorder
• The current treatment options only focus on palliative treatment rather than cure, which opens a platform of new therapies to boost the market of Alopecia areata

Scope of the Alopecia Areata Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Alopecia Areata Companies: Eli Lilly and Company/Incyte Corporation, Pfizer, Legacy Healthcare, Pfizer, Q32 Bio Inc., AbbVie, Amgen, Concert Pharmaceuticals, Bristol-Myers Squibb, Reistone Biopharma, Inmagene LLC, Suzhou Zelgen Biopharma, Nektar Therapeutics, AnaptysBio, Inc., LEO Pharma, Eli Lilly and Company, and others
• Key Alopecia Areata Therapies: OLUMIANT (baricitinib), LITFULO (ritlecitinib), Etrasimod, Coacillium (LH-8), PF-06651600, ADX-914, Upadacitinib, Daxdilimab, CTP-543, Deucravacitinib, SHR0302, IMG-007, Jaktinib, Rezpegaldesleukin, Rosnilimab, LEO 124249, Baricitinib, and others
• Alopecia Areata Therapeutic Assessment: Alopecia Areata current marketed and Alopecia Areata emerging therapies
• Alopecia Areata Market Dynamics: Alopecia Areata market drivers and Alopecia Areata market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Alopecia Areata Unmet Needs, KOL's views, Analyst's views, Alopecia Areata Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.